Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Third Quarter Earnings
January 04 2008 - 8:35AM
PR Newswire (US)
NEW YORK, Jan. 4 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE:FRX), an international manufacturer and marketer of
pharmaceutical products, will release its Fiscal 2008 Third Quarter
financial results before the U.S. stock market opens on Tuesday,
January 15, 2008. Later that day, at 10:00 AM EST, Forest will host
a conference call where Dr. Lawrence Olanoff, President and Chief
Operating Officer and Frank Perier, Senior Vice President and Chief
Financial Officer, will discuss the financial results and relevant
company and industry topics. The conference call will be webcast
live beginning at 10:00 AM EST on the Company's website
http://www.frx.com/ and also on the website
http://www.streetevents.com/. Please log on to either website at
least fifteen minutes prior to the conference call as it may be
necessary to download software to access the call. A replay of the
conference call will be available until January 31, 2008 at both
websites and also by dialing 1-800-642-1687 (US investors) or
+1-706-645-9291 (international investors), ID 30069630. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) About
Forest Laboratories and Its Products Forest Laboratories
(http://www.frx.com/) is a US-based pharmaceutical company
dedicated to identifying, developing and delivering products that
make a positive difference in peoples' lives. Forest Laboratories'
growing product line includes Lexapro(R) (escitalopram oxalate), an
SSRI indicated for adults for the initial and maintenance treatment
of major depressive disorder and generalized anxiety disorder;
Namenda(R) (memantine HCl), an N-methyl D-aspartate (NMDA)-receptor
antagonist indicated for the treatment of moderate to severe
Alzheimer's disease; and Campral(R)* (acamprosate calcium),
indicated in combination with psychosocial support for the
maintenance of abstinence from alcohol in patients with alcohol
dependence who are abstinent at treatment initiation. In addition
to our growing product line, Forest also co-promotes the Daiichi
Sankyo, Inc. products Benicar(R)* (olmesartan medoxomil), an
angiotensin receptor blocker, Benicar HCT(R)* (olmesartan
medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and
diuretic combination product, and AZOR(TM)* (amlodipine and
olmesartan medoxomil) a calcium channel blocker and angiotensin
receptor blocker combination product, all indicated for the
treatment of hypertension. *Azor is a trademark of Daiichi Sankyo,
Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi
Sankyo, Inc.; and Campral is a registered trademark of Merck Sante
s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany. Except for
the historical information contained herein, this release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform act of 1995. These statements involve
a number of risks and uncertainties, including the difficulty of
predicting FDA approvals, the acceptance and demand for new
pharmaceutical products, the impact of competitive products and
pricing, the timely development and launch of new products, and the
risk factors listed from time to time in each of Forest
Laboratories' Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q, and any subsequent SEC filings.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
http://photoarchive.ap.org/ DATASOURCE: Forest Laboratories, Inc.
CONTACT: Charles E. Triano, Vice President - Investor Relations of
Forest Laboratories, Inc., +1-212-224-6714, Web site:
http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024